Case study shows that site activation is a key driver in determining patient enrollment cycle time, which can be minimized by identifying the "sweet spot" of sites to deploy for a clinical trial.
Valerie Legagneur
Advertisement
Articles by Valerie Legagneur
Case study demonstrates that site activation is a key driver in determining patient enrollment cycle time.
Advertisement
Latest Updated Articles
Enrollment Cycle Times Can and Should Be OptimizedPublished: January 17th 2018 | Updated:
- Enrollment Cycle Times Can and Should Be Optimized
Published: January 17th 2018 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Approves UCB’s Kygevi for TK2 Deficiency Based on Multi-Study Clinical Program Demonstrating Significant Survival and Motor Gains
2
Inside the Recruitment Bottlenecks Driving Trial Delays
3
Eli Lilly’s Phase II Trial of Eloralintide Shows Up to 20% Weight Reduction in Adults With Obesity
4
Designing Feasible Protocols with Real-World Data
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
